ATAI Fundamental Analysis - ATAI LIFE SCIENCES NV

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ATAI. ATAI was compared to 195 industry peers in the Pharmaceuticals industry. While ATAI seems to be doing ok healthwise, there are quite some concerns on its profitability. ATAI is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ATAI had negative earnings in the past year.

ATAI had a negative operating cash flow in the past year.

In the past 5 years ATAI always reported negative net income.

ATAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -76.24%, ATAI is not doing good in the industry: 69.74% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -98.17%, ATAI is in line with its industry, outperforming 40.51% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-76.24%
ROE	-98.17%
ROIC	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ATAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ATAI has been increased compared to 1 year ago.

ATAI has more shares outstanding than it did 5 years ago.

ATAI has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.05, we must say that ATAI is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.05, ATAI is in line with its industry, outperforming 54.36% of the companies in the same industry.

ATAI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.

ATAI has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: ATAI outperforms 52.82% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Altman-Z	0.05

ROIC/WACCN/A

WACC7.2%

2.3 Liquidity

ATAI has a Current Ratio of 4.07. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.

ATAI has a Current ratio of 4.07. This is in the better half of the industry: ATAI outperforms 62.56% of its industry peers.

ATAI has a Quick Ratio of 4.07. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.07, ATAI is in the better half of the industry, outperforming 64.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.07
Quick Ratio	4.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ATAI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -264.00%.

ATAI shows a decrease in Revenue. In the last year, the revenue decreased by -1.91%.

Measured over the past years, ATAI shows a very negative growth in Revenue. The Revenue has been decreasing by -75.28% on average per year.

EPS 1Y (TTM)-264%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.76%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.22% on average over the next years. This is a very strong growth

ATAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 289.39% yearly.

EPS Next Y25.97%

EPS Next 2Y8.64%

EPS Next 3Y13.23%

EPS Next 5Y30.22%

Revenue Next Year256.37%

Revenue Next 2Y-17.75%

Revenue Next 3Y421.48%

Revenue Next 5Y289.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATAI. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATAI. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ATAI's earnings are expected to grow with 13.23% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y8.64%

EPS Next 3Y13.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ATAI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (6/18/2025, 8:00:00 PM)

After market: 2.34 +0.01 (+0.43%)

2.33

+0.11 (+4.95%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-14 2025-05-14/bmo

Earnings (Next)08-11 2025-08-11/bmo

Inst Owners10.13%

Inst Owner Change73.83%

Ins Owners2.84%

Ins Owner Change28.14%

Market Cap465.53M

Analysts83.33

Price Target8.16 (250.21%)

Short Float %6.39%

Short Ratio5.48

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-22.56%

Min EPS beat(2)-62.27%

Max EPS beat(2)17.15%

EPS beat(4)1

Avg EPS beat(4)-40.11%

Min EPS beat(4)-115.21%

Max EPS beat(4)17.15%

EPS beat(8)5

Avg EPS beat(8)12.3%

EPS beat(12)7

Avg EPS beat(12)7.19%

EPS beat(16)9

Avg EPS beat(16)-10.31%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-7.69%

PT rev (3m)14.29%

EPS NQ rev (1m)25.37%

EPS NQ rev (3m)18.03%

EPS NY rev (1m)0%

EPS NY rev (3m)-8%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)91.18%

Revenue NY rev (3m)690.2%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1511.47
P/FCF	N/A
P/OCF	N/A
P/B	3.06
P/tB	3.13
EV/EBITDA	N/A

EPS(TTM)-0.91

EYN/A

EPS(NY)-0.76

Fwd EYN/A

FCF(TTM)-0.42

FCFYN/A

OCF(TTM)-0.39

OCFYN/A

SpS0

BVpS0.76

TBVpS0.74

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-76.24%
ROE	-98.17%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-52.42%

ROA(5y)-70.02%

ROE(3y)-67.79%

ROE(5y)-86.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1007.92%
Cap/Sales	1983.12%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.07
Quick Ratio	4.07
Altman-Z	0.05

F-Score3

WACC7.2%

ROIC/WACCN/A

Cap/Depr(3y)268.35%

Cap/Depr(5y)673.01%

Cap/Sales(3y)220.74%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-264%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.76%

EPS Next Y25.97%

EPS Next 2Y8.64%

EPS Next 3Y13.23%

EPS Next 5Y30.22%

Revenue 1Y (TTM)-1.91%

Revenue growth 3Y-75.28%

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year256.37%

Revenue Next 2Y-17.75%

Revenue Next 3Y421.48%

Revenue Next 5Y289.39%

EBIT growth 1Y18.39%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-10.66%

EBIT Next 3Y-10.22%

EBIT Next 5Y6.19%

FCF growth 1Y18.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y23.51%

OCF growth 3YN/A

OCF growth 5YN/A

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens